[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.

614.O2.6 Acute Lymphoblastic Leukemia - Therapy, excluding Transplantation: Clinical Trials

Program: Oral and Poster Abstracts
Type: Oral
Monday, December 6, 2010: 2:45 PM-4:15 PM
311 ABCD (Orange County Convention Center)
Moderators:
Elizabeth A. Raetz, MD, New York University Langone Medical Center and Nita L. Seibel, MD, Cancer Therapy Evaluation Prgm., NCI
2:45 PM
Inability to Tolerate Standard Therapy Is a Major Reason for Poor Outcome In Older Adults with Acute Lymphoblastic Leukemia (ALL):  Results From the International MRC/ECOG Trial

Jonathan I Sive, MBChB1*, Georgina Buck2*, Adele Fielding3, Hillard M. Lazarus, MD FACP4, Mark R. Litzow, MD5, Selina M. Luger, MD6, David I. Marks, MBBS, PHD7, Andrew McMillan, FRCP, FRCPath, PhD8, Susan M Richards, PhD2*, Jacob M. Rowe, MD9, Martin S. Tallman, MD10 and Anthony H Goldstone, MD11

1Haematology, University College London Hospital, London, United Kingdom
2Clinical Trial Service Unit, Oxford, United Kingdom
3Haematology, University College London, London, United Kingdom
4Medicine, University Hospitals Case Medical Center, Cleveland, OH
5Hematology, Mayo Clinic, Rochester, MN
6University of Pennsylvania, Philadelphia, PA
7Molecular and Cellular Medicine, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
8Centre for Clinical Haematology, Nottingham City Hosp., Nottingham, United Kingdom
9Hematology and Bone Marrow Transplantation, Rambam Medical Center, Technion, Haifa, Israel
10Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY
11North London Cancer Network, Univ. College London Hosp., London, United Kingdom

3:00 PM
PEG-Asparaginase Intensification In Adult Acute Lymphoblastic Leukemia (ALL): Significant Improvement of Outcome with Moderate Increase of Liver Toxicity In the German Multicenter Study Group for Adult ALL (GMALL) Study 07/2003

Nicola Goekbuget, MD1, Anja Baumann, MD2*, Joachim Beck, MD3*, Monika Brueggemann, MD4*, Helmut Diedrich, MD5*, Andreas Huettmann, MD6*, Lothar Leimer, MD7, Stefan Zewen, MD8*, Martin Mohren, MD9*, Albrecht Reichle, MD10*, Markus Schaich, MD11*, Kerstin Schaefer-Eckart, MD12*, Marc Schmalzing, MD13*, Mathias Schmid, MD14*, Hubert Serve, MD1, Reingard Stuhlmann, MD15*, Theis H Terwey, MD16* and Dieter Hoelzer, MD1

1Department of Medicine II, Goethe University Hospital, Frankfurt, Germany
2University Hospital Munich-Großhadern, Munich, Germany
3University Hospital, Mainz, Germany
4University Hospital Kiel, Kiel, Germany
5Hannover Medical School, Hannover, Germany
6Hematology, University Hospital, Essen, Germany
7Robert-Bosch-Krankenhaus, Stuttgart, Germany
8Krankenhaus München-Schwabing, München, Germany
9University Hospital Magdeburg, Magdeburg, Germany
10University Hospital, Regensburg, Germany
11Department of Medicine II, University of Dresden, Dresden, Germany
12Klinikum Nürnberg-Nord, Nürnberg, Germany
13Abteilung II für Onkologie, Hämatologie, Immunologie, Rheumatologie und Pulmologie, Medizinische Universitätsklinik Tübingen, Tübingen, Germany
14University Hospital, Ulm, Germany
15Asklepios Klinik St. Georg, Hamburg, Germany
16Charite University Hospital, Berlin

3:15 PM
Excellent Outcome for ETV6/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia (ALL) with Contemporary Therapy

Deepa Bhojwani, MD1, Deqing Pei, MS2*, John Sandlund, MD1*, Sima Jeha, MD1*, Raul C. Ribeiro, MD1, Jeffrey E. Rubnitz, MD, PhD1, Susana C. Raimondi, PhD3, Sheila Shurtleff, PhD3*, Mihaela Onciu, MD3, Cheng Cheng, PhD4*, Elaine Coustan-Smith, MS1*, W. Paul Bowman, MD5*, Scott C. Howard, MD, MS1, Monika L. Metzger, MD, MS1*, Hiroto Inaba, MD, PhD1, Wing H. Leung, MD.PhD1*, William E. Evans, PharmD6, Dario Campana, MD, PhD7, Mary V. Relling, PharmD6 and Ching-Hon Pui, MD1

1Oncology, St. Jude Children's Research Hospital, Memphis, TN
2Biostatistics, St. Jude Children's Research Hospital, Memphis, TN
3Pathology, St. Jude Children's Research Hospital, Memphis, TN
4Biostatistics, St Jude Children's Research Hospital, Memphis, TN
5Department of Hematology/Oncology, Cook Children's Medical Center, Fort Worth, TX
6Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN
7Oncology and Pathology, St. Jude Children's Research Hospital, Memphis, TN

3:30 PM
UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia

Ajay J. Vora, FRCPATH1, Chris Mitchell, FRCPCH2*, Nicholas Goulden, FRCPATH3* and Sue Richards, DSc4*

1Dept. of Pediatric Hematology, The Children's Hospital, Sheffield, United Kingdom
2Paediatric Oncology, John Radcliffe Hospital, Oxford, United Kingdom
3Paediatric Haematology, Great Ormond Street Hospital, London, United Kingdom
4Clinical Trials Service Unit, University of Oxford, Oxford, United Kingdom

3:45 PM
Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children’s Cancer Group (CCG) Study 1991Clinically Relevant Abstract

Yousif Matloub, MD1, Bruce C. Bostrom, MD2*, Stephen Hunger, MD3, Anne Angiolillo, MD4*, Meenakshi Devidas, PhD5, Mei La6*, Nyla A. Heerema, PhD7, Naomi Winick, MD8*, James Nachman, MD9, Harland Sather, PhD6*, William L. Carroll, MD10* and Paul S Gaynon, MD11*

1Pediatric Hematology/Oncology, Rainbow Babies & Children's Hospital, Cleveland, OH
2Pediatric Hem/Onc, Childrens Hospitals and Clinics of Minnesota, Minneapolis, MN
3Pediatric Hem./Onc./BMT, University of Colorado School of Medicine, Aurora, CO
4Chiildren's National Medical Center, Washington, DC
5Department of Biostatistics, College of Medicine, University of Florida, Gainesville, FL
6Children's Oncology Group, Arcadia, CA
7Pathology, The Ohio State University, Columbus, OH
8Pediatric Hematology-Oncology, University of Texas Southwestern Medical Center, Dallas, TX
9Dept. of Pediatric Hem./Onc., Univ. of Chicago Children's Hosp., Chicago, IL
10New York University Medical Center/NYU Cancer Institute, New York, NY
11Division of Hem-Onc, Children's Hospital of Los Angeles, Los Angeles, CA

4:00 PM
Improved Prognosis for Older Adolescents with Acute Lymphoblastic Leukemia

Sima Jeha, MD1*, Deqing Pei, MS2*, Dario Campana, MD, PhD3, W. Paul Bowman, MD4*, John Sandlund, MD1*, Sue Kaste, DO5*, Raul C. Ribeiro, MD1*, Jeffrey E. Rubnitz, MD, PhD1, Elaine Coustan-Smith, MS1*, Cheng Cheng, Ph.D.2*, Monika L. Metzger, MD, MS1*, Deepa Bhojwani, MD1, Hiroto Inaba, MD, PhD1, Susana C. Raimondi, PhD6, Mihaela Onciu, MD6, Scott C. Howard, MD, MS1, Wing H. Leung, MD.PhD1*, James R. Downing, MD6, William E. Evans, PharmD7, Mary V. Relling, PharmD7 and Ching-Hon Pui, MD1

1Oncology, St. Jude Children's Research Hospital, Memphis, TN
2Biostatistics, St. Jude Children's Research Hospital, Memphis, TN
3Oncology and Pathology, St. Jude Children's Research Hospital, Memphis, TN
4Department of Hematology/Oncology, Cook Children's Medical Center, Fort Worth, TX
5Radiological Sciences, St. Jude Children's Research Hospital, Memphis
6Pathology, St. Jude Children's Research Hospital, Memphis, TN
7Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN

*signifies non-member of ASH